Nanoparticle targeted drug delivery system

Nanoparticle targeted drug delivery system

1. NANoPARTICLES Presented By Bindiya Patel M.PHARM (PHARMACEUTICS)

2. CONTENTS 1. INTRODUCTION 2. CONCEPT 3. ADV AND DISADV 4. IDEAL CHARACTERISTICS 5. METHOD OF PREPARATION 6. CHARACTERIZATION 7. EVALUATION 8. APPLICATIONS 2

3. INTRODUCTION DEFINITION: Nanoparticles are subnanosized colloidal drug delivery systems particle size ranges from 10-1000 nm in diameter. They are composed of synthetic or semi synthetic polymers carrying drugs or proteinaceous substances, i.e. antigen(s ). Drugs are entrapped in the polymer matrix particulates or solid solutions or may be bound to particle surface by physical adsorption or in chemical form. 3

4. CONCEPT The basic Concept involved is : Selective and Effective Localization of pharmacologically active moiety at preselected target(s) in therapeutic concentration,, Provided restriction of it’s access to non-target normal tissues and cells. Nanoparticles are mainly taken by : Reticulo Endothelial System (RES), After the administration ; 4

5. Hence are useful to carry drugs to the liver and to cells that are phagocytically active. By modifying the surface characteristics of the nanoparticles it is possible to enhance the delivery of drugs to spleen relative to the liver. Distribution of the nanoparticles in the body may be achieved possibly by : C oating of nanoparticles with certain Serum components, Attachment of antibodies or sulfoxide groups and the use of Magnetic nanoparticles. 5

6. ADVANTAGES Reduction in the frequency of the dosages taken by the patient More uniform effect of the drug R eduction of drug Side Effects Reduced fluctuation in circulating drug levels Avoids hepatic first pass metabolism 6

7. DISADVANTAGES H igh cost Productivity more difficult Reduced ability to adjust the dose Highly sophisticated technology Requires skills to manufacture Difficult to maintain stability of dosage form. E.g.: Resealed erythrocytes stored at 4 C . 7

8. IDEAL CHARACTERISTICS It should be biochemical inert , non toxic and non-immunogenic. It should be stable both physically and chemically in Invivo & invitro conditions. Restrict drug distribution to non-target cells or tissues or organs & should have uniform distribution. Controllable & Predicate rate of drug release. 8

9. Drug release should not effect drug action Specific Therapeutic amount of drug release must be possessed Carriers used must be biodegradable or readily eliminated from the body without any problem and no carrier induced modulation in disease state . The preparation of the delivery system should be easy or reasonable simple , reproducible & cost effective.   9

10. Method of preparation A : Cross Linking Methods 1) By Cross-linking of Amphiphilic Macromolecules 2) By Crosslinking in W/O Emulsion 3) By Emulsion chemical dehydration 4) By Phase Separation 5) By pH lnduced Aggregation B : Polymerization Methods 1) Emulsion polymerization 2) Dispersion polymerization 10

11. 1) By Cross-linking of Amphiphilic Macromolecules Nanoparticles can be prepared from Amphiphilic macromolecules, proteins and polysaccharides (which have affinity for aqueous and lipid solvents ). The method involves Aggregation of Amphiphiles followed by stabilization either by heat denaturation or chemical cross-linking 2 ) By Cross linking in W/O Emulsion Emulsification of bovine serum albumin (BSA) OR human serum albumin (HSA) or protein aqueous solution in oil using high-pressure homogenization or high frequency sonication. 11

12. Aqueous protein (BSA ) Oil W/O emulsion Dilution with preheated oil (100 o C) (Heat cross-linking) Or Addition of crosslinking agent (Chemical cross-linking ) Centrifugation and isolation of nanoparticles Emulsification using high-pressure homogenization or high frequency sonication Surfactant 12

13. 3) Emulsion Chemical Dehydration Stabilization can also be achieved by emulsion chemical dehydration . Hydroxy propyl cellulose solution in chloroform is used as a continuous phase, while a chemical dehydrating agent, 2,2 , di-methyl propane is used to disperse into the internal aqueous phase to form an Emulsion. ADV : The method avoid coalescence of droplets and could produce nanoparticles of smaller size (300nm ), 13

14. 4) Phase seperation The protein or polysaccharide from an aqueous phase can be D esolvated by : A) pH change B) Change in temperature C) Addition of appropriate counter ions e.g. alginate 14

15. Aqueous phase(protein aqueous solution ) Protein aggregates (Coacervates) Protein colloidal dispersion Nanoparticles dispersion (External aqueous phase) 200nm Desolvation Resolvation Cross-linking Heat to 40 o C , subsequent cooling to 4 O C for 24h. 15

16. 5) pH lnduced Aggregation Gelatin Nanospheres were prepared by : Gelatin & tween 20 were dissolved in aq. phase & pH of the solution was adjusted to optimum value. The clear solution so obtained was heated to 40 C followed by its quenching at 4 C for 24hrs & subsequently left at ambient temperature for 48hrs. The sequential temperature treatment resulted into a colloidal dispersion of aggregated gelatin. The aggregates were finally cross linked using glutaraldehyde as cross linking agent the optimum pH was 5.5- 6.5.values below 5.5 produced no aggregation while above 6.5 an uncontrolled aggregation led to the formation of larger nanospheres 16

17. Polymerization based methods 1) Emulsion polymerization : IT CONSISTS OF : A] Micellar nucleation and polymerization : Monomer is insoluble in continuous phase.(O/W phase) Aqueous p hase B] Homogenous nucleation and polymerization : Monomer is soluble in continuous phase.(W/O phase) Organic phase. 17

18. Monomer bearing Nucleated micelle Stabilized polymeric micelle nanospheres Catalyst Monomer droplet Catalyst Drug Monomer monomer supply (micelle) (nanospheres) Micellar nucleation and polymerization 18

19. Homogenous nucleation and polymerization 19

20. 2] Dispersion polymerization lsolation of nanospheres Oligomers aggregate & precipitates Further, By chemical initiation (ammonium or potassium per oxo disulphate ) (Acrylamide or Methyl methacrylate) Monomer is dissolved in an aqueous medium Heated to above 65 C 20

21. Solvent Evaporation Method

22. Solvent Displacement Method

23. 23 Salting out of Polymer

24. Characterization and evaluation of nanopatricles PARAMETER METHOD 1) Particle size - Photon correlation spectroscopy - Laser defractometry - Scanning electron microscopy 2) Molecular weight - Gel Chromatography 3) Charge determination - Laser Doppler Anemometry - Zeta potentiometer 24

25. 4 ) Density - Helium compression pynometry 5) Crystallinity - X-ray diffraction & Differential scanning Calorimetry, Thermogravimetry 6) Hydrophobicity - Hydrophobic interaction , Chromatography 7) Surface element analysis - X-ray , photon electron 25

26. 8) Specific Surface Area : specific surface area A = 6 / Density x diameter of particle 9) Invitro Release : > Diffusion Cell . > Recently Introduced Modified Ultra Filtration Technique. > Media Used : Phosphate Buffer 10) Nanoparticle Yield : % yield = Actual weight of Product X 100 Total weight of Drug and Excipients 26

27. Applications 1) Widely used in case of Cancer Therapy. 2) In lntracellular Targeting 3) Used for Prolonged Systemic Circulation. 4) As a Vaccine Adjuvant. 5) In Case of Ocular delivery. 6) Used in DNA Delivery. 7) It is used in case of Oligonucleotide delivery. 8) Enzyme immunoassays 9) Radio-imaging. 10) To cross BBB. 27

28. 28 Applications Application Purpose Material Cancer therapy Targeting, Reduced toxicity, enhance uptake of anti-tumor agent Polyalkylcyanoacrylate with anticancer agent Intra cellular targeting Target reticuloendothelial system for intracellular infection Poly alkyl cyanoarylate Vaccine adjuvant Prolong systemic drug effect. Enhance immune response Poly methyl metha acrylate nanoparticles with vaccines DNA delivery Enhanced bioavailability and significantly higher expression level DNA gelatin nanoparticles , DNA chitosan nanoparticles Ocular delivery Improved retention of the drug and reduced washed out. Poly alkyl cyanoacrylate nanoparticles , anti-inflammatory agent

29. 29

30. REFERENCE Targetted and controlled drug delivery by S.P. VYAS and R.K. KHAR Jain N.K. “Advances in controlled and novel Drug Delivery”, CBS publisher & Distributers, Edition 1st 2001, Pg. 408 Nanotechnology in drug delivery - A Review, Indian Drugs, Issue 11,november 2011. http://en.wikipedia.org/wiki/Nanoparticle http://www.pharmainfo.net/reviews/nanoparticles-review 30

31. 31